Tavapadon

AbbVie Inc's emraclidine failed two Phase 2 trials for schizophrenia, impacting Bristol Myers Squibb's Cobenfy competition. Despite this, analysts remain positive on AbbVie's immunology franchise, though BMO Capital Markets lowered their price target to $208.

AbbVie's emraclidine fails in two Phase II schizophrenia studies, shifting focus to Parkinson's drug tavapadon from Cerevel acquisition. BMS may benefit in schizophrenia space.

AbbVie's stock dropped 13% after emraclidine, a schizophrenia drug from its $8.7 billion Cerevel Therapeutics acquisition, failed in phase 2 trials. The failure benefits Bristol-Myers Squibb, whose Cobenfy received FDA approval in September, and Neurocrine Biosciences, which had a successful phase 2 trial for its M4 agonist.

AbbVie lost $40 billion in market value after its experimental drug emraclidine failed two clinical trials for schizophrenia. Despite the setback, AbbVie remains focused on neuroscience and has a diverse portfolio of brain medicines. The failure of emraclidine removes a competitive threat for Bristol Myers' Cobenfy, an approved antipsychotic.

The FTC's 2023 revised merger guidelines impact pharmaceutical industries with stricter HHI and market share requirements, emphasizing direct evidence of market dominance and ecosystem competition. The FTC scrutinizes pharmaceutical mergers for market concentration, innovation, and entry barriers, with ongoing investigations into Novo Nordisk/Catalent and AbbVie/Cerevel mergers. The EC investigates Zoetis for potential abuse of dominance post-merger, and the FTC challenges fraudulent patents to prevent market monopolization. Pharmaceutical companies are increasingly merging with biotech firms to offset patent expirations and enhance product portfolios.

FDA approves AbbVie's Vyalev, a subcutaneous drug for advanced Parkinson's disease, after two prior rejections. Vyalev is the first 24-hour continuous levodopa-based therapy, already launched in 34 countries. AbbVie plans to use data from four clinical studies for tavapadon, acquired through the Cerevel Therapeutics deal, to seek further regulatory approvals.

AbbVie’s Vyalev, a 24-hour continuous subcutaneous infusion of foscarbidopa and foslevodopa, approved by FDA for treating motor fluctuations in advanced Parkinson’s disease. Vyalev showed superior improvement in 'on' time without troublesome dyskinesia and decreased 'off' time compared to oral CD/LD in clinical trials.

FDA approves AbbVie's Vyalev, a 24-hour infusion therapy using prodrug versions of carbidopa and levodopa for advanced Parkinson's patients, based on clinical trial results showing improved motor fluctuations and symptom control.

AbbVie and Novartis are recommended as 'forever' dividend stocks, with AbbVie overcoming Humira's patent loss and Novartis focusing on innovative medicines post-spinoff, both offering strong dividend yields.